Table 4 XPD codon 751 polymorphism and HCC risk stratified by HBV infection (HBsAg- negative and positive), HCV infection (anti-HCV- negative and positive), and gender (female and male)

153

75.0

86

51.2

Reference

Reference

32

15.7

56

33.3

3.11(1.87-5.18)

2.36(1.25-4.45)^b

19

9.3

26

15.5

2.44(1.27-4.46)

1.42(0.60-3.36)^b

51

25.0

82

48.8

2.86(1.85-4.43)

2.01(1.16-3.51)^b

311

61.2

186

41.3

Reference

Reference

155

30.5

166

36.9

1.79(1.35-2.38)

1.52(1.08-2.16)^b

42

8.3

98

21.8

3.90(2.60-5.85)

2.64(1.60-4.37)^b

197

38.8

264

58.7

2.24(1.73-2.90)

1.77(1.29-2.43)^b

387

66.3

223

44.2

Reference

Reference

150

25.7

185

36.7

2.14(1.63-2.81)

1.93(1.39-2.70)^d

47

8.0

96

19.0

3.55(2.41-5.21)

2.93(1.82-4.72)^d

197

33.7

281

55.8

2.48(1.94-3.17)

2.17(1.60-2.94)^d

77

60.2

49

43.0

Reference

Reference

37

28.9

37

32.5

1.57(0.88-2.81)

1.28(0.70-2.34)^d

14

10.9

28

24.6

3.14(1.51-6.55)

2.77(1.29-5.93)^d

51

39.8

65

57.0

2.00(1.20-3.34)

1.68(0.99-2.85)^d

133

77.3

65

38.2

Reference

Reference

33

19.2

81

47.6

5.02(3.04-8.30)

5.64(3.33-9.56)^f

6

3.5

24

14.1

8.19(3.19-21.01)

8.58(3.28-22.46)^f

39

22.7

105

61.8

5.51(3.44-8.83)

6.12(3.72-10.05)^f

331

61.3

207

46.2

Reference

Reference

154

28.5

141

31.5

1.46(1.10-1.95)

1.50(1.12-2.01)^f

55

10.2

100

22.3

2.91(2.00-4.22)

2.90(1.99-4.21)^f

209

38.7

241

53.8

1.84(1.43-2.38)

1.88(1.45-2.43)^f